ARMA is pleased to welcome new associate member AbbVie to its membership.
AbbVie is a research-based biopharmaceutical company discovering and delivering transformational medicines and products in several key therapeutic areas such as immunology. AbbVie invests in research to discover, develop and deliver new medicines. They target diseases with significant unmet need where we can improve the standard of care with innovative new therapies. They aim to create solutions that go beyond treating the illness to have a positive impact on patients’ lives, on societies—and on science itself.…
Read more of this article
NOA Webinar: COVID Orthopaedic Recovery: National and International recruitment
The Nuffield Foundation, in partnership with Versus Arthritis, has announced £4 million for new research funding to improve the social and economic wellbeing of people living with musculoskeletal conditions in the UK. Applicants should develop interdisciplinary proposals that can help identify, develop and enhance non-clinical policy and practice interventions.
The All Party Parliamentary Group (APPG) for Osteoporosis and Bone Health published a report into the long-standing postcode lottery in the NHS for osteoporosis care. The report highlights the scale of under-diagnosis, under-treatment and missed opportunities in the NHS, with a blueprint for change. Implementation of the blueprint in England and Wales could save the NHS around £287m over five years – a return on investment of around 3:1 – according to the Royal Osteoporosis Society (ROS), which has supported the Inquiry.… 
PCRMM webinar: National Early Inflammatory Arthritis Audit (NEIAA)
Dr Ledingham will be justifying the need for and the potential benefits of the Audit; she will clarify what it is looking at and why, offering insights into latest performance and on how data can be used for QI activity.… 
The following links were added to the chat during the webinar: